酒精性肝病患者戒酒失败原因分析*

doi:10.3969/j.issn.1672-5069.2023.06.015

实用肝脏病杂志 ›› 2023, Vol. 26 ›› Issue (6): 827-830.doi: 10.3969/j.issn.1672-5069.2023.06.015

酒精性肝病患者戒酒失败原因分析^*

夏洁, 张亚飞, 李芳, 徐思洁, 张振华

230601 合肥市安徽医科大学第二附属医院感染病科

收稿日期:2023-01-03 出版日期:2023-11-10 发布日期:2023-11-20
通讯作者: 张振华,E-mail:zzh1974cn@163.com
作者简介:夏洁,女,27岁,硕士研究生,医师。主要从事酒精性肝病临床防治研究。E-mail:1071426582@qq.com
共同第一作者:张亚飞,男,41岁,副主任医师。E-mail:zhangyafei198@126.com
基金资助:
^* 安徽省自然科学基金资助项目(编号:2108085MH298);安徽医科大学学科建设项目(编号:2021lcxk027);安徽省高校科学研究项目(编号:KJ2021A0323)

Reasons of failed alcohol abstinence in patients with alcoholic liver diseases

Xia Jie, Zhang Yafei, Li Fang, et al

Department of Infectious Diseases, Second Affiliated Hospital, Anhui Medical University,Hefei 230601,Anhui Province, China

Received:2023-01-03 Online:2023-11-10 Published:2023-11-20

摘要/Abstract

摘要： 目的探讨酒精性肝病(ALD)患者戒酒失败的原因。方法 2021年2月～2022年6月我院诊治的ALD或ALD合并其他肝病男性患者149例,在初次门诊就诊时采取劝戒方法戒酒。采用酒精应用障碍筛查量表(AUDIT)调查,应用二元多因素Logistic回归分析影响戒酒失败的因素。结果在149例ALD患者中,单纯ALD 88例,合并慢性乙型肝炎(CHB)49例,合并其他慢性肝病12例;轻症肝病27例,脂肪肝36例,酒精性肝炎14例和肝硬化/原发性肝癌72例;在随访3个月时,戒酒失败53例(35.6%),戒酒成功96例(64.4%);戒酒成功组年龄、饮酒≥30年、合并肝病和酒精依赖占比分别为(54.8±11.3)岁、56.3%、50.0%和16.7%,与戒酒失败组比[分别为(49.6±11.5)岁、28.3%、24.5%和60.4%],差异显著(P＜0.05);戒酒成功组轻症肝病、脂肪肝、肝炎和肝硬化/肝癌占比分别为17.7%、15.6%、6.3%和60.4%,与戒酒失败组(分别为18.9%、39.6%、15.1%和26.4%)比,差异显著(P＜0.05);二元Logistic回归分析发现,有酒精依赖、单纯ALD、轻症肝病、脂肪肝和肝炎是影响ALD患者随访3个月时戒酒失败的独立危险因素(P＜0.05)。结论超过1/3的ALD或ALD合并其他肝病患者戒酒失败,酒精依赖单纯ALD和病情轻为戒酒失败的独立危险因素,应予以重视。

关键词: 酒精性肝病, 戒酒, 酒精依赖, 病情, 影响因素

Abstract: Objective The aim of this study was to investigate the reasons of failed alcohol abstinence in patients with alcoholic liver diseases (ALD). Methods A total of 149 male patients with ALD or ALD with concomitant other liver diseases were admitted to our hospital between February 2021 and June 2022, and all were persuaded and encouraged for alcohol abstinence at first visit. The alcoholic behavior was evaluated by alcohol use disorders identification test (AUDIT), and the univariate and multivariate Logistic analysis was conducted for the factors of alcohol abstinence failure. Results The patients in our series included ALD in 88 cases, with concomitant chronic hepatitis B in 49 cases and with other liver diseases in 12 cases, characterized by mild liver disease in 27 cases, fatty liver in 36 cases, alcoholic hepatitis in 14 cases and liver cirrhosis (LC) or primary liver cancer (PLC) in 72 cases; at the end of three-month of follow-up, the alcohol abstinence failed in 53 cases (35.6%) and succeeded in 96 cases (64.4%); the ages, and the percentages of alcohol abuse longer than 30 yr, with concomitant other liver diseases and alcohol dependence in succeeded patients were (54.8±11.3)yr, 56.3%, 50.0% and 16.7%, significantly different compared to [(49.6±11.5)yr, 28.3%, 24.5% and 60.4%] in failed patients (P＜0.05); the percentages of mild liver diseases, fatty liver, alcoholic hepatitis and LC/PLC in succeeded patients were 17.7%, 15.6%, 6.3% and 60.4%, significantly different compared to 18.9%, 39.6%, 15.1% and 26.4% in failed patients (P＜0.05); the multivariate Logistic analysis showed that the alcohol dependence, simple ALD, mild liver diseases, fatty liver and alcoholic hepatitis were the main risk factors for short-term failed alcohol abstinence (P＜0.05). Conclusion More than one-third (35.6%) of patients with ALD or ALD with other liver diseases fail to abstain from drinking, and the alcohol dependence ALD alone and mild illness are the independent risk factors for abstinence failure.

Key words: Alcoholic liver diseases, Alcohol dependence, Severity of illness, Alcohol abstinence, Influencing factor

夏洁, 张亚飞, 李芳, 徐思洁, 张振华. 酒精性肝病患者戒酒失败原因分析^*[J]. 实用肝脏病杂志, 2023, 26(6): 827-830.

Xia Jie, Zhang Yafei, Li Fang, et al. Reasons of failed alcohol abstinence in patients with alcoholic liver diseases[J]. Journal of Practical Hepatology, 2023, 26(6): 827-830.

参考文献

[1] Xiao J, Wang F, Wong NK, et al. Epidemiological realities of alcoholic liver disease: global burden, research trends, and therapeutic promise. Gene Expr, 2020,20(2):105-118.
[2] Osna NA, Ganesan M, Seth D, et al. Second hits exacerbate alcohol-related organ damage: an update. Alcohol Alcohol, 2021,56(1):8-16.
[3] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.酒精性肝病防治指南(2018年更新版). 实用肝脏病杂志, 2018,21(2):170-176.
[4] Xiao J, Wang F, Wong NK, et al. Global liver disease burdens and research trends: analysis from a Chinese perspective. Hepatology, 2019,71(1):212-221.
[5] Wong T, Dang K, Ladhani S, et al. Prevalence of alcoholic fatty liver disease among adults in the United States, 2001-2016. JAMA, 2019,321(17):1723-1725.
[6] Blachier M, Leleu H, Peck-Radosavljevic M, et al.The burden of liver disease in Europe: a review of available epidemiological data. Hepatology, 2013,58(3):593-608.
[7] Testino G, Leone S, Borro P. Treatment of alcohol use disorder patients affected by liver cirrhosis and/or hepatocellular carcinoma awaiting liver transplantation. Minerva Med, 2016,107(4):223-238.
[8] 张改霞, 陈海震, 黄晶. 酒精性肝病患者肠道微生态变化研究进展. 实用肝脏病杂志, 2022,25(05):757-760.
[9] 冯宇, 杜振元, 李艳彬, 等. 酒精性肝病患者血清IL-17水平及其基因-197A/G位点单核苷酸多态性分析. 实用肝脏病杂志, 2022,25(1):58-61.
[10] Singal AK, Bataller R, Ahn J, et al. ACG clinical guideline: alcoholic liver disease. Am J Gastroenterol, 2018,113(2):175-194.
[11] European Association for the Study of the Liver. EASL clinical practice guidelines: Management of alcohol-related liver disease.Hepatology, 2018,69(1):154-181.
[12] Dousset C, Kajosch H, Ingels A, et al. Preventing relapse in alcohol disorder with EEG-neurofeedback as a neuromodulation technique: A review and new insights regarding its application. Addict Behav, 2020,106:106391.
[13] Zheng SH, Li YM, Chen SH, et al. Alcoholic liver disease. Are there any differences between China and Western countries in clinical features? Saudi Med J, 2014,35(7):753-756.
[14] Saunders JB, Aasland OG, Babor TF, et al. Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption--II. Addiction, 1993,88(6):791-804.
[15] 张聪, 杨国平, 李圳, 等. 中文版酒精使用障碍筛查量表信度和效度评价. 中华流行病学杂志, 2017,38(8):1064-1067.
[16] Garcia ML, Blasco-Algora S, Fernandez-Rodriguez CM. Alcohol liver disease: a review of current therapeutic approaches to achieve long-term abstinence. World J Gastroenterol, 2015,21(28):8516-8526.
[17] Higgins-Biddle JC, Babor TF. A review of the alcohol use disorders identification test (AUDIT), AUDIT-C, and USAUDIT for screening in the United States: past issues and future directions. Am J Drug Alcohol Abuse, 2018,44(6):578-586.
[18] Reinert DF, Allen JP. The alcohol use disorders identification test: an update of research findings. Alcohol Clin Exp Res, 2007,31(2):185-199.
[19] Maryconi MJ, Mitchell SC. Therapy for alcoholic liver disease. World J Gastroenterol, 2014,20(9):2143-2158.
[20] Rehm J, Taylor B, Mohapatra S, et al. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis. Drug Alcohol Rev, 2010,29(4):437-445.
[21] 中华医学会, 中华医学会杂志社, 中华医学会消化病学分会, 等. 酒精性肝病基层诊疗指南(2019年). 中华全科医师杂志, 2020,19(11):990-996.

酒精性肝病患者戒酒失败原因分析^*

Reasons of failed alcohol abstinence in patients with alcoholic liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	涂建军, 方翔, 蒋琪, 李翠玉. 乙型肝炎肝硬化并发食管胃底静脉曲张破裂出血患者再出血影响因素及预测模型的建立^*[J]. 实用肝脏病杂志, 2023, 26(5): 686-689.
[2]	陈丽, 郭明君, 操依含, 曹秀玲, 周静. 瞬时弹性成像检查肝组织硬度诊断酒精性肝硬化效能研究^*[J]. 实用肝脏病杂志, 2023, 26(4): 524-527.
[3]	李荣, 曹晶晶, 李晶, 潘峰. 慢加急性/亚急性乙型肝炎肝衰竭患者发病诱因及影响临床转归因素分析^*[J]. 实用肝脏病杂志, 2022, 25(6): 832-835.
[4]	张改霞, 陈海震, 黄晶. 酒精性肝病患者肠道微生态变化研究进展^*[J]. 实用肝脏病杂志, 2022, 25(5): 757-760.
[5]	彭书甲, 周帅. 经皮肝穿刺胆道取石治疗胆总管结石患者影响引流持续时间的因素分析^*[J]. 实用肝脏病杂志, 2022, 25(4): 587-590.
[6]	冯宇, 杜振元, 李艳彬, 刘红. 酒精性肝病患者血清IL-17水平及其基因-197A/G位点单核苷酸多态性分析^*[J]. 实用肝脏病杂志, 2022, 25(1): 58-61.
[7]	刘丽霞, 林应源, 李华敏, 蔡水苗. 劳拉西泮与奥沙西泮治疗酒精性肝病并发酒精戒断综合征患者临床疗效对比研究[J]. 实用肝脏病杂志, 2021, 24(5): 709-712.
[8]	张英, 张雷, 丁海涛. TACE术后阿帕替尼维持治疗进展期肝细胞癌患者疗效分析^*[J]. 实用肝脏病杂志, 2021, 24(5): 733-736.
[9]	利振坤, 何吕芬, 李欢, 符晓莹, 王身华, 吴智明. 慢加急性肝衰竭并发侵袭性真菌感染患者临床特点及其影响因素分析[J]. 实用肝脏病杂志, 2021, 24(4): 520-523.
[10]	高慧茹, 高会斌, 彭昭, 王璐, 霍小辉. 乙型肝炎肝硬化并发食管胃底静脉曲张破裂出血患者临床特征及影响因素分析[J]. 实用肝脏病杂志, 2021, 24(3): 395-398.
[11]	陈燕屏, 黄绍强, 邓鑫, 熊超. 硫普罗宁联合多烯磷脂酰胆碱治疗酒精性肝病患者疗效及血清TLR4、MD-2和TGF-β1水平变化[J]. 实用肝脏病杂志, 2021, 24(1): 67-70.
[12]	伍畅, 田园, 刘洪岩. 酪酸梭菌活菌辅助硫普罗宁和美他多辛治疗酒精性肝病患者疗效及其对患者肠道菌群分布的影响[J]. 实用肝脏病杂志, 2021, 24(1): 75-78.
[13]	郭文成, 李娜, 王芳, 张宁, 刘燕. TACE联合¹³¹I美妥昔单克隆抗体灌注治疗原发性肝癌患者近期疗效研究[J]. 实用肝脏病杂志, 2020, 23(6): 877-880.
[14]	栗红江, 何福亮, 陈来印. 酒精性肝病患者血清LP、LPO、NOS水平和肠道菌群分布变化分析^*[J]. 实用肝脏病杂志, 2020, 23(4): 536-539.
[15]	黄庆勇, 张万里, 陈怡发, 刘黎明, 方菊梅. 经皮肝穿刺胆管造瘘电子胆道镜取石术治疗肝内胆管结石患者并发症发生及其影响因素分析^*[J]. 实用肝脏病杂志, 2020, 23(4): 601-604.